← All trials
NCT06526117
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2024
- Primary completion
- Dec 31, 2029
- Completion date
- Jun 30, 2030
- First posted
- Jul 29, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 220
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Vanderbilt UniversityOfficial
- Murtala Muhammed Specialist HospitalCollaborator
- Aminu Kano Teaching HospitalCollaborator
- Vanderbilt UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.